ImmunityBio (IBRX) announced the opening of a new Phase 2 study to assess the BioShield platform, anchored by Anktiva, in patients with long COVID.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment
- ImmunityBio announces early findings from QUILT-106 trial
- ImmunityBio says VA hospital among first to administer ANKTIVA
- ImmunityBio’s Shareholder Settlement Gains Preliminary Approval
- ImmunityBio’s ANKTIVA: Expanding Oncology Potential and Market Growth Drive Buy Rating